The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.

摘要: Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness limited by low adherence. Antiretroviral drug formulations that require infrequent dosing may increase adherence and thus PrEP effectiveness. We investigated whether monthly injections of long-acting formulation the integrase inhibitor GSK1265744 (GSK744 LA) prevented simian/human immunodeficiency virus (SHIV) infection vaginal challenge in macaques. Female pigtail macaques (n = 12) were exposed to intravaginal inoculations SHIV twice week for up 11 weeks. Half animals received GSK744 LA injection every 4 weeks, half placebo. LA, at plasma concentrations achievable quarterly humans, protected all six from infection. Placebo controls infected after median (range, 2 20) challenges SHIV. Efficacy was related high sustained remained above protein-adjusted 90% inhibitory concentration during cycles. These data support advancement as potential candidate women.